Becton Dickinson and Company Common Stock (BDX) fair value

ACCE thesis

Becton Dickinson makes syringes, IV catheters, blood collection tubes, and diagnostic testing systems, with its Medical segment and Life Sciences business both supplying hospitals and labs. Its scale in disposable medical devices and installed base of diagnostic instruments give it recurring consumable revenue that is hard to displace once a hospital standardizes on its products. Revenue growth of 5.4% is steady rather than spectacular, and the 46.9% gross margin reflects pricing power in a category where clinicians rarely switch suppliers mid-contract. The stock trades at a forward P/E of 13.7 against a trailing P/E of 43.5, a gap that mostly reflects one-time charges depressing reported earnings, so the question for a portfolio manager is whether normalized earnings support the forward multiple. With a 15.7% operating margin and a 6.6% ROE, the business is profitable but not yet earning strong returns on its equity base, which is the part of the thesis that needs deeper work.